A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)

This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts. After the first part, some participants will be randomly chosen again to either get a higher dose or stop the drug.

NCT Number	NCT07519395
Lead Sponsor	GlaxoSmithKline
Conditions	Irritable Bowel Syndrome
Enrollment	420 participants
Start Date	2026-04-08
Primary Completion	2027-03-09 (estimated)
Study Completion	2027-07-13 (estimated)
Updated on ClinicalTrials.gov	2026-06-25